Previous 10 | Next 10 |
BioLife Solutions press release (NASDAQ:BLFS): Q1 GAAP EPS of -$0.17 beats by $0.09. Revenue of $36.22M (+115.0% Y/Y) misses by $1.98M. For further details see: BioLife Solutions GAAP EPS of -$0.17 beats by $0.09, revenue of $36.22M misses by $1.98M
BioLife Solutions Reports First Quarter 2022 Financial Results PR Newswire Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of $159.5 mil...
BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022 PR Newswire BOTHELL, Wash. , May 2, 2022 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bio...
The shares of BioLife Solutions (NASDAQ:BLFS) have recorded the highest intraday gain eight months after Oppenheimer upgraded the healthcare supplier to Outperform from Market Perform, citing its undervaluation. BioLife (BLFS) manufactures and supplies bioproduction tools and services for the...
A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company's growth by acquisition strategy. There are also management changes and the...
Being a logistics service provider for the booming cell/gene therapy sector, Cryoport is enjoying the robust industry tailwind and thereby positioning itself to be an investment bonanza. Various acquisitions like MVE Biological Solutions and CryoPDP are delivering leaping top-line gro...
BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP PR Newswire BOTHELL, Wash. , April 7, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-def...
BioLife Solutions (NASDAQ:BLFS) receives a non-compliance notice from Nasdaq as it failed to file its Annual Report on Form 10-K for the year ended December 31, 2021 with the SEC. Company has 60 calendar days or until May 16, 2022 to submit a plan to regain compl...
BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing PR Newswire BOTHELL, Wash. , March 18, 2022 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and suppli...
BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K PR Newswire BOTHELL, Wash. , March 17, 2022 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of clas...
News, Short Squeeze, Breakout and More Instantly...
BioLife Solutions Inc. Company Name:
BLFS Stock Symbol:
NASDAQ Market:
BioLife Solutions Inc. Website:
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024 PR Newswire BOTHELL, Wash. , July 25, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction...
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouv...
BioLife Solutions Reports First Quarter 2024 Financial Results PR Newswire Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands ...